Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
NCT ID: NCT01059786
Last Updated: 2025-06-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
69 participants
INTERVENTIONAL
2010-07-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies. One nonstandard treatment for HCL is rituximab, an antibody that binds to the cancer cells and helps the immune system destroy them. By combining rituximab with other anti-cancer drugs, researchers hope to determine whether the combined drugs are successful in treating HCL.
* Pentostatin and bendamustine are two anti-cancer drugs that have been used to treat different kinds of blood and immune system cancers. Bendamustine is approved to treat other kinds of leukemia and lymphoma, but it has not been used to treat HCL. Pentostatin has been used for more than 20 years to treat HCL, but it has not been combined with rituximab in official clinical trials.
Objectives:
* To determine whether rituximab with either pentostatin or bendamustine is a more effective treatment for HCL than rituximab alone.
* To determine whether pentostatin or bendamustine is a more effective treatment for HCL when combined with rituximab.
Eligibility:
\- Individuals at least 18 years of age who have been diagnosed with hairy cell leukemia that has not responded well to or has relapsed after standard HCL therapies.
Design:
* The study will last for four treatment cycles of 28 days each.
* Prior to the study, participants will be screened with a full medical history and physical exam, bone marrow biopsy (if one has not been performed in the last 6 months), computed tomography (CT) or ultrasound scan, tumor measurements, and other tests as required by the researchers. Participants will provide blood and urine samples at this time as well.
* Rituximab with bendamustine: Participants will receive rituximab on Days 1 and 15 of each cycle and bendamustine on Days 1 and 2 of each cycle, for a total of four cycles.
* Rituximab with pentostatin: Participants will receive rituximab on Days 1 and 15 of each cycle and pentostatin on rituximab on Days 1 and 15 of each cycle, for a total of four cycles.
* Participants will have regular tests during the treatment cycles, including bone marrow biopsies and CT or ultrasound scans. Participants will also provide regular blood and urine samples to assess the results of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT02168907
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03518112
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
NCT02168140
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT01238146
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
NCT01326702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Hairy cell leukemia (HCL) is highly responsive to purine analogs cladribine and pentostatin, without evidence of cure. Neither is standard after 2 courses, due to cumulative marrow and T-cell toxicity and declining remission rates and durations. Once resistant, patients after multiple relapses can die of disease-related cytopenias.
* Rituximab alone in 51 patients from 5 trials who had cytopenias and at least 1 prior purine analog resulted in 10 complete + 10 partial remissions (complete response (CR) + partial response (PR) = overall response rate (ORR 39%).
* Rituximab with cladribine gives high CR rates in 1st or 2nd line but is not standard.
* While cladribine use is more common for 1st and 2nd line, pentostatin is often used for subsequent treatment because of \< 100% cross-resistance.
* Retrospective published data for pentostatin plus rituximab in HCL include 7 of 7 responses with 6 (86%) CRs, and there are no prospective data.
* Recombinant immunotoxins targeting cluster of Differentiation 25 (CD25) (LMB-2) and cluster of differentiation-22 (CD22) (CAT-3888 (BL22) and R490A (HA22) are highly active in purine analog resistant HCL. Palliative pentostatin-rituximab is often used off-protocol for patients with immunogenicity needing more therapy.
* Bendamustine is approved for early treatment of chronic lymphocytic leukemia (CLL) and is effective with rituximab for relapsed/refractory CLL. Its use in HCL is unreported.
* CRs with minimal residual disease (MRD) by immunohistochemistry (IHC) of bone marrow biopsy (BMBx IHC), can relapse early. Tests for HCL MRD in blood or marrow include flow cytometry (fluorescence-activated cell sorting (FACS) or polymerase chain reaction (PCR) using consensus primers. The most sensitive MRD test in HCL is real-time quantitative PCR using sequence-specific primers (real-time quantitative polymerase chain reaction (RQ-PCR).
* Of 5 HCL-specific trials listed on Cancer.gov, 2 are phase II trials of cladribine + rituximab in 1st and 2nd line (1 randomized at National Institutes of Health (NIH), 1 non-randomized at MDA), and 3 NIH phase I-II trials of recombinant immunotoxins BL22, HA22 and LMB-2.
Objectives:
-Primary:
--To determine if pentostatin + rituximab and bendamustine + rituximab are each associated with adequate response rates (ORR=PR+CR) in patients with relapsed HCL, and, if so, to select which combination is likely to be superior.
Eligibility:
* HCL needing therapy, either greater than or equal to 2 prior courses of purine analog, 1 course purine analog plus greater than or equal to 1 course rituximab if \< 1 year response to the 1 course purine analog, diagnosis of HCL variant (HCLv), or unmutated immunoglobulin heavy variable 4-34 (IGHV4-34+) expressing HCL/HCLv.
* Prior treatment, ineligibility for, or patient refusal of recombinant immunotoxin.
Design:
* Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles (all 72 patients).
* Initial tolerability study: 12 patients receive rituximab + bendamustine (nonrandom), including 6 at 70 mg/m\^2 and 6 at 90 mg/m\^2 of bendamustine.
* Randomize: 1) 28 patients to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle 2) 28 patients to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
* Non-randomized: up to 4 patients to receive either bendamustine 90 mg/m\^2P2P/day, days 1 and 2 each cycle or pentostatin 4 mg/m\^2P2P days 1 and 15 of each cycle.
* Statistics: If \> 14/28 respond, can conclude with 90% power that response \> 40% in that arm. \>80% probability of selecting the better arm if true response probability is approximately 40-50% on the inferior arm and \>15% higher on the superior arm.
* Stratify to equalize the % of patients/arm refractory to last course of purine analog.
* Accrual Ceiling: 72 evaluable participants
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 - Non-Randomized to 70 mg/m^2 Bendamustine-Rituximab
Rituximab + Bendamustine at 70 mg/m\^2 for initial tolerability study (closed)
Rituximab
Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
Bendamustine
1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
Acetaminophen
Treatment of infusion-related symptoms with acetaminophen is recommended.
Diphenhydramine
Treatment of infusion-related symptoms with diphenhydramine is recommended.
Epinephrine
Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Antihistamines
Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Corticosteroids
Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Bronchodilators
Additional treatment with bronchodilators may be indicated.
Intravenous (IV) Saline
Additional treatment with intravenous (IV) saline may be indicated.
Arm 2 - Non-randomized to 90 mg/m^2 Bendamustine-Rituximab
Rituximab + Bendamustine at 90 mg/m\^2 for initial tolerability study (closed)
Rituximab
Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
Bendamustine
1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
Acetaminophen
Treatment of infusion-related symptoms with acetaminophen is recommended.
Diphenhydramine
Treatment of infusion-related symptoms with diphenhydramine is recommended.
Epinephrine
Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Antihistamines
Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Corticosteroids
Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Bronchodilators
Additional treatment with bronchodilators may be indicated.
Intravenous (IV) Saline
Additional treatment with intravenous (IV) saline may be indicated.
Arm 3 - Randomized to 90 mg/m^2 Bendamustine-Rituximab
Rituximab + Bendamustine (at the tolerated dose)
Rituximab
Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
Bendamustine
1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
Acetaminophen
Treatment of infusion-related symptoms with acetaminophen is recommended.
Diphenhydramine
Treatment of infusion-related symptoms with diphenhydramine is recommended.
Epinephrine
Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Antihistamines
Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Corticosteroids
Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Bronchodilators
Additional treatment with bronchodilators may be indicated.
Intravenous (IV) Saline
Additional treatment with intravenous (IV) saline may be indicated.
Arm 4 - Randomized to Pentostatin-Rituximab
Rituximab + Pentostatin
Pentostatin
28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
Rituximab
Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
Acetaminophen
Treatment of infusion-related symptoms with acetaminophen is recommended.
Diphenhydramine
Treatment of infusion-related symptoms with diphenhydramine is recommended.
Epinephrine
Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Antihistamines
Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Corticosteroids
Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Bronchodilators
Additional treatment with bronchodilators may be indicated.
Intravenous (IV) Saline
Additional treatment with intravenous (IV) saline may be indicated.
Non-randomized to Bendamustine 90mg/m^2 or Pentostatin 4mg/m^2 with Rituximab
After initial tolerability studies are completed. Non-randomize up to 4 total participants to Bendamustine and/or Pentostatin with Rituximab
Pentostatin
28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
Rituximab
Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
Bendamustine
1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
Acetaminophen
Treatment of infusion-related symptoms with acetaminophen is recommended.
Diphenhydramine
Treatment of infusion-related symptoms with diphenhydramine is recommended.
Epinephrine
Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Antihistamines
Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Corticosteroids
Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Bronchodilators
Additional treatment with bronchodilators may be indicated.
Intravenous (IV) Saline
Additional treatment with intravenous (IV) saline may be indicated.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pentostatin
28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
Rituximab
Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
Bendamustine
1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
Acetaminophen
Treatment of infusion-related symptoms with acetaminophen is recommended.
Diphenhydramine
Treatment of infusion-related symptoms with diphenhydramine is recommended.
Epinephrine
Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Antihistamines
Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Corticosteroids
Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Bronchodilators
Additional treatment with bronchodilators may be indicated.
Intravenous (IV) Saline
Additional treatment with intravenous (IV) saline may be indicated.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* bone marrow biopsy (BMBx) or bone marrow aspiration (BMA) consistent with HCL, confirmed by National Institutes of Health (NIH) Laboratory of Pathology, NCI, or the Department of Laboratory Medicine, Clinical Center, NIH, unless the diagnosis can be confirmed from a solid (lymph node) mass.
* Treatment indicated based on demonstration of at least one of the following, no more than 4 weeks from the time of enrollment, and no less than 6 months after prior cladribine and no less than 4 weeks after other prior treatment, if applicable.
* Neutropenia (Absolute neutrophil count (ANC) less than 1000 cells/microl).
* Anemia (Hemoglobin (Hgb) less than 10g/dL).
* Thrombocytopenia (Platelet (PLT) less than 100,000/microl).
* Absolute lymphocyte count (ALC) of greater than 5,000 cells/microL
* Symptomatic splenomegaly.
* Enlarging lymph nodes greater than 2cm.
* Repeated infections requiring oral or intravenous (i.v.) antibiotics.
* Increasing lytic bone lesions
Patients who have eligible blood counts within 4 weeks from enrollment will not be considered ineligible if subsequent blood counts prior to enrollment fluctuate and become ineligible up until the time of enrollment.
* One of the following:
* At least 2 prior courses of purine analog
* 1 prior course of purine analog plus greater than or equal to1 course of rituximab if the response to the course of purine analog lasted less than 1 year.
* Diagnosis of HCL variant (HCLv)
* Unmutated (\>98% homology to germline) immunoglobulin heavy variable 4-34 (IGHV4-34+) expressing hairy cell leukemia (HCL)/HCLv
* Eastern Cooperative Oncology Group (ECOG) performance status (102) of 0-3
* Patients must be able to understand and give informed consent.
* Creatinine less than or equal to 1.5 or creatinine clearance greater than or equal to 60 ml/min.
* Bilirubin less than or equal to 2 unless consistent with Gilbert's (total/direct greater than 5), alanine transaminase (ALT) and aspartate aminotransferase (AST) less than or equal to 3 x upper limits of normal.
* No other therapy (i.e., chemotherapy, interferon) for 4 weeks prior to study entry, or cladribine for 6 months prior to study entry, unless progressive disease more than 2 months after cladribine is documented.
* Age at least 18
* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment.
* Patients must be willing to co-enroll in the investigators companion protocol 10-C-0066 titled Collection of Human Samples to Study Hairy Cell and other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment.
Exclusion Criteria
* Uncontrolled coronary disease or New York Heart Association (NYHA) class III-IV heart disease.
* Known infection with human immunodeficiency virus (HIV), hepatitis B or C.
* Pregnant or lactating women.
* Presence of active 2nd malignancy requiring treatment. 2nd malignancies with low activity which do not require treatment (i.e., low grade prostate cancer, basal cell or squamous cell skin cancer) do not constitute exclusions.
* Inability to comply with study and/or follow-up procedures.
* Presence of central nervous system (CNS) disease
* Patients with history of non-response to both pentostatin plus rituximab and to bendamustine plus rituximab.
* Receipt of a live vaccine within 4 weeks prior to randomization. Efficacy and/or safety of immunization during periods of B-cell depletion have not been adequately studied. It is recommended that a patients vaccination record and possible requirements be reviewed. The patient may have any required vaccination/booster administered at least 4 weeks prior to the initiation of study treatment. Review of the patient's immunization status for the following vaccinations is recommended: tetanus; diphtheria; influenza; Pneumococcal polysaccharide; Varicella; measles, mumps and rubella (MMR); and hepatitis B. Patients who are considered to be at high risk for hepatitis B virus (HBV) infection and for whom the investigator has determined that immunization is indicated should complete the entire HBV vaccine series at least 4 weeks prior to participation in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert Kreitman, M.D.
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert J Kreitman, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bouroncle BA. Thirty-five years in the progress of hairy cell leukemia. Leuk Lymphoma. 1994;14 Suppl 1:1-12.
Kreitman RJ, Cheson BD. Malignancy: Current Clinical Practice: Treatment of Hairy Cell Leukemia at the Close of the 20th Century. Hematology. 1999;4(4):283-303. doi: 10.1080/10245332.1999.11746452.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
Schroeder B, Yuan CM, Wang HW, Mohindroo C, Zhou H, Raffeld M, Xi L, Arons E, Feurtado JC, James-Echenique L, Calvo KR, Maric I, Kreitman RJ. Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia. Blood. 2025 Oct 8:blood.2025031243. doi: 10.1182/blood.2025031243. Online ahead of print.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form: Cohort Eligibility Consent
Document Type: Informed Consent Form: Affected Patients Consent
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-C-0025
Identifier Type: -
Identifier Source: secondary_id
100025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.